JP6596697B2 - Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩 - Google Patents

Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩 Download PDF

Info

Publication number
JP6596697B2
JP6596697B2 JP2018543858A JP2018543858A JP6596697B2 JP 6596697 B2 JP6596697 B2 JP 6596697B2 JP 2018543858 A JP2018543858 A JP 2018543858A JP 2018543858 A JP2018543858 A JP 2018543858A JP 6596697 B2 JP6596697 B2 JP 6596697B2
Authority
JP
Japan
Prior art keywords
component
pharmaceutically acceptable
composition
acid
synthesis example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018066427A1 (ja
Inventor
道夫 山村
成人 立石
Original Assignee
ブリベンションファーマシューティカル（シャンハイ）インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリベンションファーマシューティカル（シャンハイ）インコーポレイテッド filed Critical ブリベンションファーマシューティカル（シャンハイ）インコーポレイテッド
Publication of JPWO2018066427A1 publication Critical patent/JPWO2018066427A1/ja
Application granted granted Critical
Publication of JP6596697B2 publication Critical patent/JP6596697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018543858A 2016-10-03 2017-09-27 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩 Active JP6596697B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016195505 2016-10-03
JP2016195505 2016-10-03
JP2017184731 2017-09-26
JP2017184731 2017-09-26
PCT/JP2017/034926 WO2018066427A1 (ja) 2016-10-03 2017-09-27 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019131162A Division JP2019203007A (ja) 2016-10-03 2019-07-16 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Publications (2)

Publication Number Publication Date
JPWO2018066427A1 JPWO2018066427A1 (ja) 2019-07-25
JP6596697B2 true JP6596697B2 (ja) 2019-10-30

Family

ID=61832036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543858A Active JP6596697B2 (ja) 2016-10-03 2017-09-27 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩
JP2019131162A Pending JP2019203007A (ja) 2016-10-03 2019-07-16 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019131162A Pending JP2019203007A (ja) 2016-10-03 2019-07-16 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Country Status (16)

Country Link
US (1) US10828303B2 (enExample)
EP (1) EP3520795B1 (enExample)
JP (2) JP6596697B2 (enExample)
KR (1) KR20190065315A (enExample)
CN (2) CN113559102B (enExample)
AU (1) AU2017340594B2 (enExample)
BR (1) BR112019006429A2 (enExample)
CA (1) CA3039027A1 (enExample)
CO (1) CO2019003255A2 (enExample)
IL (1) IL265688A (enExample)
MX (1) MX2019003837A (enExample)
PH (1) PH12019500636A1 (enExample)
SG (1) SG11201902599SA (enExample)
TW (1) TW201818939A (enExample)
WO (1) WO2018066427A1 (enExample)
ZA (1) ZA201902341B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
IT202000015895A1 (it) 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6223429A (ja) * 1985-07-24 1987-01-31 Ishikawajima Harima Heavy Ind Co Ltd 水素同位体の回収・貯蔵・供給装置
JPS62234029A (ja) * 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
TW248552B (enExample) 1993-06-01 1995-06-01 Onoda Yakuhin Kogyo Kk
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005105722A1 (ja) * 2004-04-28 2005-11-10 Ono Pharmaceutical Co., Ltd. (２ｒ)−２−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
TWI585071B (zh) * 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
PT2443120T (pt) * 2009-06-16 2017-02-08 Rspr Pharma Ab Forma cristalina de pemirolast
CN102786414B (zh) * 2012-08-15 2014-07-16 四川大学 一类用于治疗和/或预防神经退行性相关疾病的化合物

Also Published As

Publication number Publication date
NZ752311A (en) 2020-12-18
MX2019003837A (es) 2019-06-24
CN113559102A (zh) 2021-10-29
CO2019003255A2 (es) 2019-04-12
IL265688A (en) 2019-05-30
US20190240221A1 (en) 2019-08-08
CN113559102B (zh) 2023-01-03
KR20190065315A (ko) 2019-06-11
TW201818939A (zh) 2018-06-01
CA3039027A1 (en) 2018-04-12
ZA201902341B (en) 2020-08-26
CN110267661B (zh) 2021-08-03
JP2019203007A (ja) 2019-11-28
JPWO2018066427A1 (ja) 2019-07-25
EP3520795A1 (en) 2019-08-07
PH12019500636A1 (en) 2019-10-28
BR112019006429A2 (pt) 2019-06-25
AU2017340594A1 (en) 2019-04-18
US10828303B2 (en) 2020-11-10
SG11201902599SA (en) 2019-05-30
CN110267661A (zh) 2019-09-20
EP3520795B1 (en) 2023-06-14
EP3520795A4 (en) 2020-05-13
AU2017340594B2 (en) 2020-09-10
WO2018066427A1 (ja) 2018-04-12

Similar Documents

Publication Publication Date Title
ES2587978T3 (es) Forma cristalina de (s)-4-hidroxi-2-oxo-1-pirrolidina acetamida, método de preparación y uso de la misma
JP5841672B2 (ja) Ｎ−ベンジルアニリン誘導体及びその使用
CN105001165A (zh) 取代的二氨基嘧啶其组合物，和用其治疗的方法
JP2016511273A (ja) Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型
CN102234287B (zh) 硝基咪唑类化合物、其制备方法和用途
KR20210097100A (ko) 2-(1-아실옥시-n-펜틸)벤조산 및 염기성 아미노산 또는 아미노구아니딘이 형성하는 염, 이의 제조 방법 및 용도
JP6596697B2 (ja) Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩
CN108239095A (zh) 一类吡喃并咔唑生物碱及其制备方法和其药物组合物与用途
ES2277960T3 (es) Base libre de la amlodipina.
KR20090085081A (ko) 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
WO2019119832A1 (zh) 用于代谢性疾病治疗的化合物及其制备方法和应用
TWI462915B (zh) 一種組織胺ｈ３受體拮抗劑的新穎富馬酸鹽
CN113166071A (zh) 尼拉帕利盐
JP2022106788A (ja) 脂質化ペプチドの水溶性塩、その製造方法および用途
WO1994029303A1 (en) Heterocyclic chemistry
CN118139863A (zh) 单酰基甘油脂肪酶抑制剂的结晶形式
NZ752311B2 (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
HK40005518A (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
JP7138799B2 (ja) コリンエステラーゼ阻害剤結晶多形及びその使用
JPWO2003087091A1 (ja) キノキサリンジオン誘導体無水物の新規結晶
TW202448418A (zh) 發炎性腸道疾病之治療
EA050218B1 (ru) Производные 6-метилурацила, обладающие антихолинэстеразной активностью, и их применение
JP2008504369A (ja) １，２４（ｓ）−ジヒドロキシビタミンｄ２の結晶形態
CN118724879A (zh) 一种氘代稠环化合物及其制备方法与用途
JP2002516611A (ja) 結晶性（−）−３ｒ，４ｒ−トランス−７−メトキシ−２，２−ジメチル−３−フェニル−４−｛４−〔２−（ピロリジン−１−イル）エトキシ〕フェニル｝クロマン水素マレエート

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190530

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190606

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190904

R150 Certificate of patent or registration of utility model

Ref document number: 6596697

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250